Panacea Index Logo

Command Palette

Search for a command to run...

HIV and its effects on bone: a primer for rheumatologists.

Current opinion in rheumatology
September 1, 2012
Lydia Gedmintas et al. (2 authors)
Journal ArticleResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tReviewHuman Study
Study Details

Study Goal

The researchers aimed to explore the role of calcium supplementation in preventing bone loss in HIV patients, particularly in relation to antiretroviral therapy (ART).

Results Summary

The study found conflicting evidence on whether calcium and vitamin D supplementation can prevent bone loss associated with specific ART regimens in HIV patients. Increased rates of osteopenia and osteoporosis were observed, but the impact on fracture risk remains unclear.

Population

HIV patients with comorbid bone complications such as osteopenia and osteoporosis.

Effective Dosage

Not specified

Duration

Not specified

Interactions

Possible interaction with antiretroviral therapy (ART) mentioned, but specifics not detailed.

Extracted Claims (6)
InterventionDirectionEndpointPopulationDosageImpactClaim #
-
increase
rates of comorbid chronic diseases such as bone complications
patients with HIV
-
increasing
#1
-
increase
rates of osteopenia and osteoporosis
the HIV population
-
increased
#2
antiretroviral therapy (ART)
increase
increased rates of osteopenia and osteoporosis
the HIV population
-
possibly the effect
#3
particular ART regimens
decrease
bone mineral density
the HIV population
-
decrease
#4
particular ART regimens
increase
fracture
the HIV population
-
translates into an increased risk
#5
supplementation of vitamin D and calcium
decrease
the bone loss seen with specific ART regimens
-
-
can prevent
#6
Abstract

PURPOSE OF REVIEW: As patients with HIV are living longer because of effective treatments, rates of comorbid chronic diseases such as bone complications are increasing. There is a growing body of literature showing increased rates of osteopenia and osteporosis in the HIV population. Less is known about the risk of fracture, as well as other bone complications, such as avascular necrosis (AVN). RECENT FINDINGS: Increased rates of osteopenia and osteoporosis are seen in the HIV population, likely secondary to an interaction of traditional osteoporotic and HIV-specific risk factors, and possibly the effect of antiretroviral therapy (ART). There are conflicting recent data as to whether the decrease in bone mineral density seen in the HIV population, specifically with particular ART regimens, translates into an increased risk of fracture. Conflicting evidence emerges from recent studies exploring whether supplementation of vitamin D and calcium can prevent the bone loss seen with specific ART regimens. SUMMARY: Bone disease is common in the HIV population, and will likely be a medical problem increasingly seen by rheumatologists. The role of ART regimens on bone complications such as fracture and AVN is unclear, and further research in this area as well as possible prevention strategies are needed.

Medical Subject Headings (MeSH)
Anti-HIV AgentsBone DensityBone DiseasesBone Diseases, MetabolicFractures, BoneHIV InfectionsHumansOsteonecrosisOsteoporosisRisk Factors
Study Links
Quality Scores
SafetyNot Assessed
Efficacy50/10
Quality70/10
Citation Metrics
Total Citations10
Citations/Year0.8
Relative Citation Ratio0.39
NIH Percentile20.8%
Research Impact Scores
APT Score0.50
Weight Score1.25
Normalized Score0.54
Related Supplements
HIV and its effects on bone: a primer for rheumatologists. | Panacea Index